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Abstract
Background: Although elevated levels of lactoferrin provide a biomarker for inflammatory bowel diseases and
colorectal cancer, the clinical significance of these elevated levels in ascitic fluid of patients with ascites caused by
liver cirrhosis is limited. The aims of our study were to investigate the usefulness of ascitic fluid lactoferrin levels for
the diagnosis of spontaneous bacterial peritonitis (SBP) in patients with cirrhosis and to evaluate the association
between lactoferrin levels and the development of hepatocellular carcinoma (HCC).
Methods: A total of 102 patients with ascites caused by cirrhosis were consecutively enrolled into the study, from
December 2008 to December 2011. Ascitic fluid lactoferrin levels were quantified using a human lactoferrin
enzyme-linked immunosorbent assay kit.
Results: The median ascitic fluid lactoferrin levels were significantly higher in patients with SBP than in those
without SBP (112.7 ng/mL vs. 0.6 ng/mL; p < 0.001). The area under the receiver operator characteristic curve for the
diagnosis of SBP was 0.898 (95 % confidence interval, 0.839–0.957, p < 0.001), with a sensitivity and specificity for a
cut-off level of 51.4 ng/mL of 95.8 % and 74.4 %, respectively. Moreover, the incidence of HCC in the 78 patients
without SBP was significantly higher in patients with high ascitic fluid lactoferrin levels (≥35 ng/mL) than in those
with low ascitic fluid lactoferrin level (<35 ng/mL).
Conclusions: Ascitic fluid lactoferrin level can be a useful diagnostic tool to identify SBP in patients with ascites
caused by cirrhosis. Elevated ascitic fluid lactoferrin level in patients without SBP may be indicative of a developing
hepatocellular carcinoma.
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Background
Lactoferrin is a 78-kDa iron-binding protein in the transfer-
rin family [1]. Lactoferrin is found in bovine milk, as well as
in human breast milk [2]. This iron-binding protein is also
present in mucosal secretions, including gastrointestinal
fluids, saliva, tears, semen, vaginal fluids, nasal fluid, and
bronchial mucosa [3, 4]. Lactoferrin is believed to have
several relevant functions, that include anticancer, antibac-
terial, antiviral, antifungal, antiparasitic, anti-inflammatory,
anti-oxidant and immune regulatory activities [5, 6].
During an infection or inflammatory condition, lacto-
ferrin is expressed and secreted from polymorphonuclear
cells (PMNs) and lactoferrin levels are elevated in the
body. Lactoferrin levels have been shown to increase in
the presence of infection or inflammatory condition [7].
Therefore, an elevated lactoferrin level may provide a
promising and reliable biomarker for gastrointestinal dis-
ease [8]. Lactoferrin levels are elevated not only in patients
with inflammatory bowel diseases, such as ulcerative col-
itis and Crohn’s disease, but also in patients with colorec-
tal cancer [9–12]. Recently, several studies have provided
evidence that increased systemic inflammation is associ-
ated with poor survival in various cancers [13]. In patients
with hepatocellular carcinoma (HCC), these systemic in-
flammatory responses can be detected by routine labora-
tory tests, such as levels of C-reactive protein (CRP) and
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the neutrophil-lymphocyte ratio (NLR) [14–16]. However,
the association between ascitic fluid lactoferrin levels and
the development of HCC in patients with ascites caused
by cirrhosis has not been investigated to date.
Ascites is one of the most common complications of
advanced liver disease [17]. Spontaneous bacterial peri-
tonitis (SBP) is a clinical syndrome in which ascitic fluid
becomes infected in the absence of any apparent intra-
abdominal source of peritonitis [18]. The diagnosis of SBP
is based on a manual count of PMN cells in ascitic fluid,
with counts ≥ 250 cells/mm3 indicative of SBP. However,
this method of diagnosis is operator-dependent and, there-
fore, subject to human error. Moreover, lysis of the cells
during transport to the laboratory can lead to false nega-
tive results.
Parsi et al. assessed the utility of ascitic fluid lactoferrin
level for the diagnosis of SBP in patients with cirrhosis
[19]. However, few studies have evaluated the findings of
Parsi et al. to clarify the clinical usefulness of ascitic fluid
lactoferrin level for the diagnosis of SBP in patients with
liver cirrhosis. Therefore, the aims of our study were to in-
vestigate the usefulness of ascitic fluid lactoferrin levels for
the diagnosis of SBP in patients with ascites caused by cir-
rhosis and to evaluate the association between lactoferrin
levels and the development of HCC.
Methods
Study population
A prospective cohort study group was formed by consecu-
tive enrollment of 182 patients with ascites caused by
cirrhosis, from December 2008 to December 2011, at
Gyeongsang National University Hospital in South Korea.
The inclusion criteria were: (1) known diagnosis of cirrho-
sis, (2) age ≥20 years, and (3) presence of grade 2 or 3 asci-
tes, based on the definitions of the International Ascites
Club [20]. The exclusion criteria were as follows: (1) pres-
ence of HCC (n = 75) and (2) other causes of neutrocytic
ascites, including peritoneal carcinomatosis, tuberculosis,
pancreatitis, appendicitis, and hemorrhagic ascites (n = 5).
A total of 102 patients met our inclusion and exclusion
criteria and formed our study group. The Institutional Re-
view Board of Gyeongsang National University Hospital
reviewed and approved this study and all patients provided
informed consent.
Definitions
Liver cirrhosis was defined by the presence of portal
hypertension manifested as splenomegaly, varices, ascites,
or hepatic encephalopathy, with compatible findings on
diagnostic imaging, in combination with thrombocytopenia
(<100,000/μl). The diagnosis of HCC was based on hist-
ology or typical radiological findings of hepatic nodules
on arterial enhancement and venous wash-out, contrast-
enhanced computed tomography (CT) or magnetic
resonance (MR) imaging [21]. The diagnosis of SBP
was based on a PMN count ≥250 cells/mm3 in ascitic
fluid, with or without a positive ascitic fluid or blood cul-
ture. Ascitic fluid samples were obtained from patients
with grade 2 or 3 ascites for cell count, culture and deter-
mination of lactoferrin levels.
Data collection
Clinical data including age, sex, alcohol consumption, the
presence of hypertension and/or diabetes, the etiology of
cirrhosis, and prior SBP history were obtained. At enroll-
ment, laboratory tests were performed for anti-hepatitis C
virus (HCV), hepatitis B virus surface antigen (HBsAg),
anti-hepatitis B virus surface antibody (anti-HBs), white
blood cell (WBC) count, hemoglobin level, platelet count,
prothrombin time- international normalized ratio (PT-
INR), total bilirubin, aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), gamma glutamyl transpepti-
dase, serum albumin, creatinine, CRP, and ascitic fluid
analysis, including WBC count, PMN count, and albumin
levels. In addition, the Child-Pugh score was determined.
The ascitic fluid samples (50 mL) were frozen at −70 °C
immediately after collection until analyzed. The lactoferrin
level in ascitic fluid was quantified using a human lactofer-
rin enzyme-linked immunosorbent assay kit according to
the manufacturer’s instructions (Bethyl Laboratories, Inc.,
Tokyo, Japan). This kit, designed as a sandwich ELISA,
captures human lactoferrin present in samples by anti-
lactoferrin antibody that has been pre-adsorbed on the
surface of polystyrene microtiter wells. The lactoferrin
levels were quantified by interpolating their absorbance (at
450 nm) from the standard curve.
Patient follow-up
All patients were closely monitored for clinical and bio-
chemical status, with imaging examinations, by ultra-
sound or CT, completed every 3 to 12 months. The
cumulative death rate was measured from the date of
enrollment until the date of death, the last follow-up, or
to the study end date of December 31, 2015. Assessment
of survival included data obtained by telephone inter-
view with patients or one of their family members. To
calculate the true incidence of new HCC cases based on
ascitic fluid lactoferrin levels, patients with less than
6 months of follow-up, patients diagnosed with HCC
within 6 months of enrollment or patients with SBP
were excluded. Based on these exclusion criteria, 24 pa-
tients removed from the calculation of the true inci-
dence of new HCC cases due to development of SBP
within 6 months of enrollment.
Statistical analysis
Data were presented as median (interquartile range) for
continuous variables, and as frequency and percentage
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for categorical variables. Differences between patients
with and without SBP were evaluated using the chi-
squared test or 2-tailed Fischer’s exact test for categor-
ical variables, and the Mann–Whitney test was used for
continuous variables. Bivariate correlations were per-
formed using Spearman’s Rank Correlation to evaluate
the correlation of lactoferrin levels to all other measured
study variables. Receiver operator characteristic (ROC)
analysis, area under the curve (AUC) and 95 % confi-
dence interval (CI) of the AUC were used to identify the
optimal cutoff value of lactoferrin level for the diagnosis
of SBP. A p-value <0.05 indicated statistical significance.
Statistical analyses were performed using PASW soft-
ware (Version 18, SPSS Inc., Chicago, IL, USA).
Results
Patients’ characteristics
Demographic and clinical characteristics of the 102 pa-
tients forming our study group are summarized in Table 1.
Liver cirrhosis was caused by alcohol in 64.7 %, HBV in
17.6 %, HCV in 11.8 %, and HBV +HCV in 1.0 %, with
the remaining 4.9 % of patients having a diagnosis liver of
disease from ‘other’ causes. SBP was diagnosed in 24
patients (22.9 %).
Median age, sex, disease etiology, Child-Pugh score, and
incidence of prior SBP were comparable among patients
with and without SBP. In laboratory results, median ascitic
fluid lactoferrin level, ascitic WBC count, ascitic PMN
count, serum WBC count, serum PMN count, and CRP
level were significantly higher in patients with SBP than in
those without SBP. The median ascitic fluid lactoferrin
level was 0.6 in patients without SBP and 112.7 in patients
with SBP (p <0.001).
Correlation of ascitic fluid lactoferrin level with laboratory
parameters
The correlations between ascitic fluid lactoferrin levels with
laboratory parameters are summarized in Table 2. In all pa-
tients, ascitic fluid lactoferrin levels correlated with ascitic
WBC count (r = 0.529, p <0.001), ascitic PMN count (r =
0.633, p < 0.001), serum PMN level (r = 0.200, p = 0.044),
serum platelet count (r = −0.253, p = 0.018), serum CRP
level (r = 0.355, p < 0.001), serum PT-INR (r = 0.232, p =
0.019), and the Child-Pugh score (r = 0.248, p = 0.012). In
Table 1 Baseline demographic and clinical characteristics according to spontaneous bacterial peritonitis
Total (n = 102) No SBP (n = 78) SBP (n = 24) p-value
Age, years 54.5 (45.8–62.8) 53.0 (45.8–62.0) 55.5 (45.8–68.5) 0.376
Gender, male 73 (71.6 %) 59 (75.6 %) 14 (58.3 %) 0.123
Etiology 0.983
Alcohol 66 (64.7 %) 50 (64.1 %) 16 (66.7 %)
HBV 18 (17.6 %) 14 (17.9 %) 4 (16.7 %)
HCV 12 (11.8 %) 9 (11.5 %) 3 (12.5 %)
HBV + HCV 1 (1.0 %) 1 (1.3 %) 0 (0 %)
Others 5 (4.9 %) 4 (5.1 %) 1 (4.2 %)
Child-Pugh score 11 (9–12) 11 (9–12) 11 (10–12) 0.089
Prior SBP 19 (18.6 %) 12 (15.4 %) 7 (29.2 %) 0.143
Ascitic fluid level
Lactoferrin (ng/ml) 21.7 (0–100.1) 0.6 (0–54.5) 112.7 (91.5–139.8) <0.001
WBC (cells/ml) 151 (60–416) 100.5 (48.8–181.3) 1158 (538–5651) <0.001
PMN (cells/ml) 11.5 (4.0–98.0) 6.5 (3.0–16.3) 5695 (3660–9668) <0.001
Serum level
WBC (×1000/μl) 6.2 (4.7–9.8) 5.9 (5.0–8.9) 7.6 (5.5–11.8) 0.037
PMN (×1000/μl) 3.9 (2.4–6.6) 3.7 (2.3–5.6) 5.7 (3.7–9.7) 0.006
Hemoglobin (g/dL) 9.3 (8.5–10.8) 9.3 (8.4–10.7) 9.2 (8.6–10.9) 0.862
Platelet (×1000/μl) 82.0 (50.0–127.8) 90.5 (53.0–135.3) 60.0 (47.3–105.5) 0.053
Albumin (g/dL) 2.5 (2.3–2.8) 2.6 (2.3–2.8) 2.5 (2.3–2.6) 0.190
Bilirubin (g/dL) 3.8 (2.0–7.8) 3.6 (1.9–7.7) 4.4 (2.3–12.7) 0.289
PT-INR 1.61 (1.35–2.23) 1.58 (1.33–2.07) 1.97 (1.49–2.39) 0.069
CRP (mg/L) 13.9 (6.7–21.9) 11.0 (5.2–16.4) 30.7 (18.7–68.1) <0.001
Data are presented as the median (interquartile range) for continuous data and percentages for categorical data
SBP spontaneous bacterial peritonitis, HBV hepatitis B virus, HCV hepatitis C virus, WBC White blood cells, PMN Polymorphonuclear cell, PT-INR prothrombin time-
international normalized ratio, CRP C-reactive protein
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ascitic fluid or blood cultures, 13 of the 24 SBP patients
(54.2 %) showed positive culture results for Escherichia coli
(5, 20.8 %), Klebsiella pneumoniae (4, 16.7 %), Streptococcus
species (2, 8.3 %), Candida albicans (1, 4.2 %), and Clostrid-
ium Perfringens (1, 4.2 %). The distribution of positive find-
ings in patients with SBP is summarized in Table 3. In the
24 patients with SBP, there was no significant difference in
ascitic fluid lactoferrin level between culture positive
SBP and culture negative SBP (median 126.3 ng/ml vs.
104.0 ng/ml, p = 0.122).
Usefulness of ascitic fluid lactoferrin levels for the
diagnosis of SBP
The median ascitic fluid lactoferrin level in patients with
SBP group was significantly higher than the level in pa-
tients without SBP (112.7 ng/mL vs. 0.6 ng/mL, p < 0.001;
Fig. 1). Results of the ROC analysis are shown in Fig. 2.
The area under the ROC curve for the diagnosis of SBP in
the 102 patients with ascites caused by cirrhosis was 0.898
(95 % CI, 0.839–0.957, p < 0.001). The sensitivity and spe-
cificity for different cut-off levels of ascitic fluid lactoferrin
for the diagnosis of SBP in this patient group are shown in
Table 4. At the cut-off level of 51.4 ng/mL, the sensitivity
and specificity of the test were 95.8 % and 74.4 %, respect-
ively. At the cut-off level of 63.0 ng/mL, the sensitivity and
specificity of the test were 91.7 % and 78.1 %, respectively.
Incidence of hepatocellular carcinoma
We assessed the incidence of HCC development in the
patients without SBP based on ascitic fluid lactoferrin
levels. Of the 78 patients without SBP, 4 patients devel-
oped HCC during the study period. The cumulative inci-
dence of HCC at 5 years was 17.9 % and the estimated
yearly incidence of HCC development was 3.6 % in the
first 5 years from the time of enrollment (Fig. 3). The
cumulative incidence of HCC was significantly higher in
patients with ascitic fluid lactoferrin levels ≥35 ng/mL than
in those with ascitic fluid lactoferrin levels <35 ng/L (log
rank test, p < 0.001).
Discussion
Outcomes of our study provide evidence of the clinical
usefulness of ascitic fluid lactoferrin levels in patients
with cirrhosis to differentiate those with and without
SBP. The area under the ROC for the diagnosis of SBP
in the 102 patients with ascites caused by cirrhosis was
0.898 (95 % CI, 0.839–0.957, p < 0.001). The sensitivity
and specificity of the ascitic fluid lactoferrin assay for
the diagnosis of SBP in patients with ascites caused by
cirrhosis were 95.8 % and 74.4 %, respectively, using a
cut-off fluid level of 51.4 ng/mL. Moreover, the inci-
dence of HCC development in patients without SBP was
significantly higher for patients with high ascitic fluid
lactoferrin levels, defined as a level ≥35 ng/mL.
Lactoferrin is released from PMNs during an infection
or an inflammatory condition [7]. In the 102 patients
with ascites caused by cirrhosis, lactoferrin levels in the
ascitic fluid were significantly correlated with ascitic WBC
count, ascitic PMN count, serum PMN count, serum plate-
let level, serum CRP, serum PT-INR, and the Child-Pugh
score. Especially, high ascitic fluid lactoferrin levels were
significantly correlated to inflammatory markers, including
WBC, PMN, and CRP levels. It is important to note that
the correlation of lactoferrin levels and inflammatory
markers in blood samples and ascitic fluid could be influ-
enced by lysis of PMN cells during transport to the labora-
tory, which could lead to a false negative result. Moreover,
manual measurement of the ascitic fluid and PMN count is
operator dependent, which makes quality control difficult.
Commercially available kits for the measurement ascitic
fluid lactoferrin could be used in a future development of a
qualitative bedside assay. Moreover, lactoferrin is very stable
and resistant to degradation at room temperature over an
extended period and, therefore, a bedside assay would be
feasible in making lactoferrin an important marker for SBP.
Table 2 Correlation of ascitic lactoferrin level with clinical and
laboratory variables in all patients (n = 102)
Variables r P value
Age (years) 0.082 0.415
WBC count in ascitic fluid (cells/mL) 0.529 <0.001
PMN count in ascitic fluid (cells/mL) 0.633 <0.001
Serum WBC count (cells/mL) 0.110 0.273
Serum PMN count (cells/mL) 0.200 0.044
Serum hemoglobin level (g/dL) 0.093 0.351
Serum platelet level (×1000/μl) −0.253 0.018
Serum CRP 0.355 <0.001
Serum bilirubin level (g/dL) 0.132 0.187
Serum PT-INR 0.232 0.019
Serum albumin level (g/dL) −0.023 0.820
Child-Pugh score 0.248 0.012
WBC White blood cells, PMN Polymorphonuclear cell, CRP C-reactive protein,
PT-INR prothrombin time-international normalized ratio
Table 3 Causative microorganisms of spontaneous bacterial
peritonitis (n = 24)
Organism Number (%)
Escherichia coli 5 (20.8 %)
Klebsiella pneumoniae 4 (16.7 %)
Streptococcus species 2 (8.3 %)
Candida albicans 1 (4.2 %)
Clostridium Perfringens 1 (4.2 %)
No growth 11 (45.8 %)
Data are presented as number (%)
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Parsi et al. assessed the utility of ascitic fluid lactoferrin
level for the diagnosis of SBP in patients with cirrhosis
[19] as a way of eliminating the risk for false negative re-
sults and diagnostic error associated with a manual count
of ascitic fluid PMN cells. We confirm Parsi et al.’s conclu-
sion regarding the clinical usefulness of ascitic fluid lacto-
ferrin level as a biomarker for SBP in patients with ascites.
However, our cut-off ascitic fluid lactoferrin level for the
diagnosis of SBP was lower than the level identified by
Parsi et al. A study by Ali et al. clarified the clinical
usefulness of ascitic fluid lactoferrin as a biomarker for
SBP [22]. The mean ascitic fluid lactoferrin levels was sig-
nificantly higher in SBP patients (180.8 ng/ml) compared
with patients without SBP (42.2 ng/ml, P = 0.001), with an
ascitic lactoferrin level of 88 ng/ml identified as a cut-off
on ROC analysis to distinguish patients ‘with’ and ‘with-
out’ SBP. This cut-off of 88 ng/ml to identify SBP was
lower than the cut-off ascitic lactoferrin level identified by
Parsi et al., but higher than the cut-off level in our study.
This difference in the cut-off of ascitic fluid lactoferrin
Fig. 1 Ascitic fluid lactoferrin levels in patients with and without spontaneous bacterial peritonitis; SBP, spontaneous bacterial peritonitis
Fig. 2 Receiver operating characteristic (ROC) curve of ascitic fluid lactoferrin levels for the diagnosis of spontaneous bacterial peritonitis (SBP) in
patients with cirrhosis (n = 102); the area under the curve is 0.898, with a 95 % confidence interval of 0.839 to 0.957
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level may be explained by the small sample sizes for SBP
patients in both studies and, possibly, by differences in the
etiology of cirrhosis. Thus, further multicenter studies are
required to identify an optimal cut-off ascitic lactoferrin
level for the diagnosis of SBP.
Recently, several studies provided evidence that in-
creased systemic inflammation is associated with poor
survival in various cancers [13]. In patients with HCC,
these systemic inflammatory responses can be detected
by routine laboratory tests, such as CRP level and the
NLR [14–16]. In an immunohistochemistry study of liver
biopsies in patients with viral and cryptogenic liver dis-
ease [23], lactoferrin was detected in 75 % of patients
with chronic hepatitis. In HCV specimens, lactoferrin
levels were found to increase with disease progression,
suggesting that lactoferrin may play a role in modulating
chronic liver inflammation [24]. However, there has been
no report on the association between ascitic fluid lactofer-
rin levels and the development of HCC in patients with
ascites caused by cirrhosis. Therefore, we hypothesized
that ascitic fluid lactoferrin levels in patients with local in-
flammatory ascites would be higher than those in patients
without local inflammatory ascites. The presence of ascitic
fluid lactoferrin is proportional to the reflux of neutrophil,
and local inflammation can provide a related marker for
the development of HCC. In our study, we found that as-
citic fluid lactoferrin level in patients without SBP might
be related to the development of HCC. HCC free survival
was 100 % and 45.2 % in patients with ascitic fluid lacto-
ferrin levels <35 ng/L and ≥35 ng/mL, respectively. Thus,
patients with ascitic fluid lactoferrin levels ≥35 ng/mL re-
quire more intensive surveillance for the early detection of
HCC.
To our knowledge, this is the first prospective study to
investigate the usefulness of lactoferrin levels in ascitic
fluid for the diagnosis of SBP in patients with ascites
due to cirrhosis in Korea. However, the limitations of
our study need to be acknowledged in the interpretation
and application of outcomes. Foremost, this is a single
center prospective study with a relatively small study
group, in which only 4 patients developed HCC during
the study period. However, the ascitic fluid lactoferrin
levels in these 4 patients were very high at 38.7 ng/mL,
60.5 ng/mL, 99.6 ng/mL, and 128.3 ng/mL. Therefore,
further studies with larger study group that include pa-
tients with ascites caused by cirrhosis and HCC are
needed. We also need to consider that the 102 patients
with ascites caused by cirrhosis did not present with new
onset ascites. Moreover, patients with ascites presented
with different Child-Pugh scores, which could have intro-
duced biases in our analysis of prognosis.
Conclusion
Ascitic fluid lactoferrin level can be a useful indicator of
SBP in patients with cirrhosis. Elevated ascitic fluid lacto-
ferrin level in patients without SBP appears to be a prom-
ising predictor of HCC development. Therefore, larger
Table 4 Diagnostic accuracy of ascitic fluid lactoferrin at the
different cut-off levels for detection of spontaneous bacterial
peritonitis in patients with cirrhosis (n = 102)






Data are presented as number (%)
Fig. 3 Cumulative incidence of hepatocellular carcinoma in patients with ascites caused by cirrhosis based on ascitic fluid lactoferrin level
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multicenter studies are required to elucidate the usefulness
of lactoferrin in ascitic fluid.
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